Results are in line with the update provided in January and confirm a significant improvement in cash generation. The outlook remains robust, with management bringing greater commercial focus to bear on the key Haematology Point-of-Care portfolio and driving growth in Life Sciences. We make no change to our forecasts other than to reflect the additional investment in the commercial team. This shows sustained double-digit profit growth as margins benefit from the increased focus. In this context, ....